FDA Approves Merck’s KEYTRUDA (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) Read more
Amneal and Shilpa Announce FDA Approval of BORUZU, the First Ready-to-Use Version of Bortezomib for subcutaneous administration Read more
European Commission Approves Merck’s KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults Read more
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Read more
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH Read more
Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer Read more